ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Endocrinology — U.S. revenue [legacy] by Quarter
Endocrinology — U.S. revenue ($M) [legacy] ($M)
Eli Lilly Endocrinology — U.S. revenue [legacy]: $2,348M in Q4 2019, up 11.9% from a year earlier. That is the highest of the 12 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2019 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2020-02-19) ↗
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Endocrinology — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2019 | Dec 31, 2019 | 2,348 | +11.9% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,987 | +10.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,102 | +10.6% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,874 | +9.2% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,098 | +11.6% | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,797 | +10.6% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,901 | +22.5% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,716 | +30.3% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,880 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,624 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,552 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,317 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Endocrinology — U.S. revenue [legacy] ($M), quarterly Q1 2017–Q4 2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta-endocrinology-us-legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.